Compliment Corporation is pioneering a novel approach in oncology by utilizing checkpoint inhibitors of the complement system to enhance cancer treatment efficacy. Their proprietary technology centers around a synthetic protein, Ad35K++, which is engineered to bind with significantly higher affinity to the complement-inhibitory protein CD46. This innovative protein plays a crucial role in improving the therapeutic effects of monoclonal antibodies (mAbs) by increasing cancer sensitivity to treatment, unmasking resistant tumors, and potentially addressing cancers that have become refractory to existing therapies. The company’s research indicates that Ad35K++ can effectively crosslink CD46 proteins on cancer cell membranes, leading to their internalization and degradation, thereby enhancing the anti-tumor effects of mAbs like Rituxan and Herceptin.

The therapeutic potential of Ad35K++ is further supported by preclinical studies demonstrating its ability to significantly enhance complement-dependent cytotoxicity triggered by various mAbs. The technology is particularly promising for treating B cell non-Hodgkin lymphoma (NHL), where CD46 expression is notably elevated on malignant cells, contributing to resistance against therapies like rituximab. By downregulating CD46, Compliment Corporation aims to improve the effectiveness of mAb treatments, thereby addressing a critical gap in current cancer therapies. The ease of manufacturing and low cost of goods associated with Ad35K++ also position it as an attractive candidate for commercialization in the competitive oncology market.

United States

Compliment Corporationis a start-up biotechnology company developing revolutionary therapeutics in oncology. Ourmission is to improve cancer treatment by dramatically increasing the effectiveness of cancer drugs and by reducing the toxicities associated with standard chemotherapy treatment.

Compliment Corporation

Company Details